Furthermore, HIF-hydroxylase inhibitors, such as DMOG, are also known to activate the HIF2α pathway, which may potentially have therapeutic applications to recover IBD patients from anemia, via downregulation of hepatic hepcidin expression. Here, EPAS1 is linked to inflammatory bowel disease.